With negotiations over the Trans-Pacific Partnership (TPP) fast coming to a conclusion, it is imperative that the U.S. fight to preserve strong intellectual property protections that encourage innovation in life sciences—and the most important requirement should be 12 years of data exclusivity protection for novel biologic drugs. This report analyzes the critical role of IP rights in life sciences innovation, assesses the potential economic impact of the TPP, and argues it will not generate the benefits we seek unless strong IP protections are a centerpiece.
The Imperative of Protecting Life Sciences Innovation in the TPP
Stephen Ezell March 9, 2015
To ensure the Trans-Pacific Partnership (TPP) Agreement creates a framework in which life sciences innovation flourishes throughout the TPP region, it needs to include 12 years of data protection for novel biologic drugs.